What role does DOTMA play in cationic liposomes during RNA drug development?

Do you know what role DOTMA plays in cationic liposomes in RNA drug development? In this article, AVT Xiaobian will explain it in detail.

In recent years, some achievements have been made in the application of non-viral vectors to gene zhi therapy, among which the most important is the use of cationic liposomes.

​

With the deepening of the understanding of the pathogenesis of disease at the cellular level, gene zhi therapy has become a hot topic of research. More and more attention has been paid to the search for safe and effective gene transfer vectors. At present, the main vectors used are viral vectors, such as recombinant adenovirus vectors, which have certain advantages in gene transfer due to their high transfection efficiency and targeting effect on most cells. However, because it causes some immune responses in the body and contains viral genes that can be transcribed, gene recombination or complementation may occur in the body, causing further harm to the human body.

​

Liposomes or lipid particles are composed of lipid molecules, such as phospholipids, cholesterol, etc., which are wrapped together as membrane materials. According to the charge, liposomes can be divided into neutral liposomes, negative liposomes, positive liposomes. Liposomes have been widely used in scientific research and drug development. Mixed with positive lipid molecules and neutral lipid molecules, it can be used to encapsulate nucleic acid molecules, such as DNA, RNA, small interference nucleic acids, miRNA, etc., for gene zhi therapy and gene yi system. This technology is widely used in research and development of new drugs. Liposomes or lipid molecules have also been used to encapsulate some drugs to promote drug targeting, stability, effectiveness, and reduce side effects.

At present, liposomes can not be widely used in research. The most important disadvantage of liposomes in clinical practice is that their toxicity and effectiveness limit their application, especially in drug development. Methods of improving liposomes or lipid particles are mainly carried out from several aspects: for example, composition. Liposomes and lipid particles are usually composed of a mixture of several components, including phospholipids and cholesterol. In order to enhance the stability and half-life of liposomes and particles in vivo, lipid nanoparticles are protected by a PEG molecule of lipids on the surface of liposomes and particles, and are not suitable for aggregation and phagocytosis by white blood cells. Among all the factors affecting the function and application of liposomes, the components of liposomes play an obvious role. At present, cationic liposomes dominate the market for nucleic acid applications (research and drug development). However, its toxicity and effectiveness are still the key to hinder the application of cationic liposomes.

Below, AVT Xiaobian will introduce the basic information of Cationic Lipidic Material DotMA to you:

Commodity name: Dotma

Common name: DOTMA

English name: trimethylammonium dioleopropyl chloride

Chemical name: 1, 2-didecaenooxy-3-methylammonium propane (chlorine salt)

Molecular formula: C42H84ClNO2

Manufacturer: Aweituo (Shanghai) Pharmaceutical Technology Co., Ltd

AS no. : 104872-42-6

Purpose: Cationic liposomes

Properties: white solid

Purity: above 96%

Molecular Weight: 670.575

Melting point: 35 ~ 38 ℃

Preservation condition: -20℃

Aweitol brings you high quality injectable grade cationic lipid DOTMA. In addition to DOTMA, DLIN-MC3-DMA, DMG-PEG2000, DOTAP, DC-CHOL, DODMA, DOPE, DOP-DEDA and other injectable grade excipients, Suitable for RNA liposomes. Welcome to inquire: 400-6262 623!